Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Industry
Miscellaneous Chemical Products
Location
771 Jamacha Road #512, El Cajon, California
State of incorporation
Delaware
Fiscal year end
July 31
Former names
PURE BIOSCIENCE (to 3/17/2011), INNOVATIVE MEDICAL SERVICES (to 9/2/2003)
Latest financial report
Q4 2023 - Mar 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -45.5%
Quick Ratio 16.9 % -57.9%
Return On Equity 8.24 K %
Return On Assets -209 % -65.5%
Operating Margin -174 % +23.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112 M shares +0.45%
Common Stock, Shares, Outstanding 112 M shares +0.45%
Entity Public Float 4.91 M USD -65.9%
Common Stock, Value, Issued 1.12 M USD +0.45%
Weighted Average Number of Shares Outstanding, Basic 112 M shares +0.45%
Weighted Average Number of Shares Outstanding, Diluted 112 M shares +0.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.05 M USD +16.3%
Revenue from Contract with Customer, Excluding Assessed Tax 2.06 M USD +14%
Research and Development Expense 300 K USD -7.41%
Operating Income (Loss) -3.57 M USD +11.4%
Nonoperating Income (Expense) -71 K USD -446%
Income Tax Expense (Benefit) 1.65 K USD 0%
Net Income (Loss) Attributable to Parent -3.65 M USD +9.91%
Earnings Per Share, Basic -0.04 USD/shares +20%
Earnings Per Share, Diluted -0.02 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 557 K USD -62.5%
Accounts Receivable, after Allowance for Credit Loss, Current 171 K USD +9.62%
Inventory, Net 74 K USD -63%
Assets, Current 939 K USD -51.6%
Property, Plant and Equipment, Net 147 K USD -75.1%
Assets 1.09 M USD -57.1%
Accounts Payable, Current 409 K USD +17.9%
Accrued Liabilities, Current 136 K USD +17.2%
Liabilities, Current 545 K USD +17.7%
Liabilities 2.41 M USD
Retained Earnings (Accumulated Deficit) -135 M USD -2.78%
Stockholders' Equity Attributable to Parent -1.32 M USD -164%
Liabilities and Equity 1.09 M USD -57.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -440 K USD +51.2%
Net Cash Provided by (Used in) Financing Activities 785 K USD
Net Cash Provided by (Used in) Investing Activities -33 K USD +59.3%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 112 M shares +0.45%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 345 K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 632 K USD -59.5%
Deferred Tax Assets, Valuation Allowance 30.3 M USD +2.78%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 30.3 M USD +2.78%
Depreciation 117 K USD -19.9%
Payments to Acquire Property, Plant, and Equipment 33 K USD -59.3%
Property, Plant and Equipment, Gross 1.62 M USD -2.71%
Deferred Tax Assets, Operating Loss Carryforwards 28.2 M USD +3.07%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133 M USD +0.19%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 80 K USD +27%
Interest Expense 72 K USD +800%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%